TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. - Wikidata - awgldk - TriplyDB

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

http://www.wikidata.org/entity/Q45077632

about

Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia Tim-3 and Tim-4 as the potential targets for antitumor therapy Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis.RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.Tim-3 and its role in regulating anti-tumor immunity.Human hemato-lymphoid system mice: current use and future potential for medicine.Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.Tim-3 expression in cervical cancer promotes tumor metastasis.Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS)Suppression of cancer relapse and metastasis by inhibiting cancer stemness Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells.Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.Hypoxia-inducible factors in cancer stem cells and inflammation.Targeted therapy against cancer stem cells.Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells.Understanding and targeting cancer stem cells: therapeutic implications and challenges.Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.Understanding of leukemic stem cells and their clinical implications.Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.Clonal evolution of acute leukemia genomes.Acute myelogenous leukemia stem cells: from Bench to Bedside.TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.Complexity of cancer stem cells.Stem cell maintenance and disease progression in chronic myeloid leukemia.

P2860

Q26796514-AAEC6243-F1BC-49D4-BDA3-1DF618F469D3 Q26799502-FBA4C446-7BE7-4379-B1A5-F6CBBFA738F0 Q26863081-628FCD4E-8589-49A3-915E-7E31BE4F2CFE Q28071384-31B86981-A390-41C0-8541-4D5EA6267F15 Q28073970-70AE6AF3-6268-4021-A8CC-B6E540977F7B Q28116224-82DD3AC0-310A-4514-87F3-B70D011712DE Q28117255-15E9B841-15B7-4572-98AB-E56C524D0583 Q28391575-6D5EA73F-FF91-4981-AF7C-4207531D3AEA Q30637447-23232A1F-0774-438C-B26C-9DEB02900316 Q33711497-58D6094A-7503-4981-9031-3079955760A0 Q33761878-32C57F39-C1AB-45A3-8EC8-C834F2A69A7C Q33816240-8BDFA45B-1A89-400E-AE7E-B2C82BDEC886 Q33834587-CB6F8811-AA24-4E18-9A68-AA1E0C01372A Q33909020-373FCA72-166E-47E3-A8F3-B6C7BBC06E88 Q33995307-BB298DFE-C210-403D-9D08-BB5A21BEE7F2 Q34047867-3683353C-45BB-47EE-89ED-3F5F8805948F Q34232877-147DD465-3B0E-4E2C-9441-E3C4BB3D64EE Q34497781-513FD2A2-A6E6-410C-BD07-57D8140DD3E7 Q34555771-4956767D-15BC-4140-894F-01C582BE8C5C Q34720554-4FCC4F13-20CE-44AB-8114-22E799482E83 Q35005153-0F64419D-CE9E-49BA-8786-ED9E81AD69FF Q35090120-9E4E2019-A449-422B-9E89-1765800545BD Q35146288-14ACB2DA-5565-42C3-8A09-FA6B891A9CA4 Q35217639-1242C978-D64D-468C-B884-C50098C85F33 Q35300118-C8BD7BD5-2F62-42D0-BCDA-106513BB478E Q35705992-64B627D9-A164-4478-AFFD-8F7E77076A51 Q35802983-C11F6AE8-447F-4394-B55F-0ECF381AC3B0 Q36008395-19E6EC15-1C91-4960-A93B-B3206EFE34B2 Q36163066-172BE215-7D3A-4ED5-AB81-7F7C9BDDAE35 Q36545301-53743958-37D4-44B9-80EC-998604DCA19A Q36907405-24F73C29-1F2E-4D5D-9F97-C6BF5C41058B Q37259702-85D1AB49-0BB8-4558-92B6-1B4CC9AE1DAF Q37272020-ADE41E73-C260-44F5-99F9-B50DC84B58F6 Q37616010-AF1910B9-BACA-41F2-BB58-5D1DDEA7478D Q37628931-1580908F-6AC3-4BF5-B735-F9D2DCFE2F93 Q37986426-2D8FE89F-5B26-441F-AAD6-E0B11FCD9401 Q38020081-ED77164F-FC0D-475C-82D0-B78A80D36109 Q38035447-32BBC194-B5E6-4A3E-96B3-D02BF7B659D6 Q38062506-2FFB843C-99BE-4766-A86B-BEE0F811C28A Q38095422-A71FF98B-0395-406F-A8A6-1409C8701F32

P2860

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

http://www.wikidata.org/entity/Q45077632

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

@en

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

@nl

type

label

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

@en

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

@nl

prefLabel

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

@en

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

@nl

P1433

Q45077632-F61AAC1F-9C09-47F1-9666-0318B7670D17

P1476

Q45077632-AF1ED419-F657-4292-9E66-F1A7DE188A74

P2093

Q45077632-078D961B-7B7D-4C4F-9D82-445E3A74A7DC

Q45077632-21141ECC-51F7-407A-B25A-8E413C447694

Q45077632-2A65311B-BA4F-4CE3-B9B9-BD4146EDC771

Q45077632-2AEBCB6D-83A3-46A7-8368-07E6C5A1D10E

Q45077632-825F75CF-10CC-4460-A6BC-4690E6EEE416

Q45077632-9C75A883-8F08-412D-A6E9-5E12E15F1F20

Q45077632-A9552CA3-235F-4797-89B3-2BBFDE54B3CB

Q45077632-B1C70E65-FEAB-4847-ADF8-28E5D79A31AA

Q45077632-D70FD882-CC8E-4F63-A328-9B1D3004AF74

Q45077632-E839569D-F835-4413-A7F2-5028BEA574EC

P304

Q45077632-60BE8CA9-4A71-4FE6-9463-A532E2011F78

P31

Q45077632-E476AFC3-75D3-4F70-86C5-3B2027FE463A

P356

Q45077632-53D6A8FA-3D6E-4504-93E8-6EE51E276568

P407

Q45077632-1157F49D-6B05-4095-8DE4-D79D54716C68

P433

Q45077632-B9C5A3A6-5A44-4055-A7FB-7DED411A83BE

P478

Q45077632-12555A31-6048-4834-90FE-4DAAD951C79D

P577

Q45077632-D2E1A6CB-920B-4C3D-9849-D45BAFBDC3C9

P5875

Q45077632-220C64DD-D7C3-4642-8B2A-FD2F24D1CBF2

P698

Q45077632-CB57324E-6368-46E9-B0C0-328AA89A6FB5

P921

Q45077632-3425535A-CF64-4B76-9894-D811D8113B3C

P356

J.STEM.2010.11.014

P1433

P1476

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

@en

P2093

Hiromi Iwasaki

http://www.w3.org/2001/XMLSchema#string

Katsuto Takenaka

http://www.w3.org/2001/XMLSchema#string

Koichi Akashi

http://www.w3.org/2001/XMLSchema#string

Shin-ichiro Takayanagi

http://www.w3.org/2001/XMLSchema#string

Shingo Urata

http://www.w3.org/2001/XMLSchema#string

Takahiro Shima

http://www.w3.org/2001/XMLSchema#string

Takanori Teshima

http://www.w3.org/2001/XMLSchema#string

Toshihiro Miyamoto

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Tanaka

http://www.w3.org/2001/XMLSchema#string

Yoshikane Kikushige

http://www.w3.org/2001/XMLSchema#string

P304

708-717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.STEM.2010.11.014

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49640407

http://www.w3.org/2001/XMLSchema#string

P698

21112565

http://www.w3.org/2001/XMLSchema#string

P921